All In Biotech

Drug Trial Radar · NCT06738485

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

62

Actual

Start

Jan 9, 2025

Primary completion

Sep 23, 2026

Study completion Sep 23, 2026

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, from 0 days, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than \[\<\] 1%).

Conditions

  • Congenital Hemophilia A

Interventions

  • Recombinant single-chain factor VIII (rVIII-SingleChain)Biological

    Lyophilized powder for solution for intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incremental Recovery (IR) of rVIII-SingleChainTime frame: Before, and at 30 minutes after the end of, rVIII-SingleChain administration on Day 1
  2. Maximum Concentration (Cmax) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
  3. Area Under the Plasma Concentration Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
  4. Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUC0-inf) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
  5. Half-life (t1/2) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
  6. Clearance (Cl) of rVIII-SingleChainTime frame: Before, and up to 72 hours (participants ≥ 12 years ) and 48 hours (participants < 12 years) after rVIII-SingleChain administration on Day 1
  7. Annualized Spontaneous Bleeding Rate (AsBR)Time frame: Up to 29 weeks after rVIII-SingleChain administration
  8. Number of participants who develop FVIII inhibitorsTime frame: During routine rVIII-SingleChain prophylaxis dosing, up to 29 weeks after rVIII-SingleChain administration.

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Children's Hospital

    Beijing, Beijing Municipality, China

  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • North China University of Science and Technology Affiliated Hospital

    Tangshan, Hebei, China

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Hebei, China

  • Henan children's hospital Zhengzhou children's Hospital

    Zhengzhou, Henan, China

  • Hunan Provincial Children's Hospital

    Changsha, Hunan, China

  • Nanjing Children's Hospital

    Nanjing, Jiangsu, China

  • XuZhou Children's Hospital

    Xuzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Quinghai Provincial People's Hospital

    Xining, Qinghai, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Qingdao Women and Children's Hospital

    Qingdao, Shandong, China

  • Shanghai Jiaotong University School of Medicine, Ruijin Hospital

    Shanghai, Shanghai Municipality, China

  • The second affiliated hospital of Kunming Medical University

    Kunming, Yunan, China

  • The Children's Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.